Doctoral students as co-authors are underlined (starting in 1998)

• Gottschlich A, Grünmeier R, Hoffmann GV, Nandi S, Kavaka V, Müller PJ, Jobst J, Oner A, Kaiser R, Gärtig J, Piseddu I, Frenz-Wiessner S, Fairley SD, Schulz H, Igl V, Janert TA, Di Fina L, Mulkers M, Thomas M, Briukhovetska D, Simnica D, Carlini E, Tsiverioti CA, Trefny MP, Lorenzini T, Märkl F, Mesquita P, Brabenec R, Strzalkowski T, Stock S, Michaelides S, Hellmuth J, Thelen M, Reinke S, Klapper W, Gelebart PF, Nicolai L, Marr C, Beltrán E, Megens RTA, Klein C, Baran-Marszak F, Rosenwald A, von Bergwelt-Baildon M, Bröckelmann PJ, Endres S, Kobold S. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood. 2025 Apr 3;145(14):1536-1552. doi: 10.1182/blood.2023022197.  JIF20. https://www.sciencedirect.com/science/article/pii/S0006497124114607

• Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S*, Böttcher JP*. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature, 2024; May;629(8011):417-425. doi: 10.1038/s41586-024-07254-x. * share senior authorship. JIF 64.8. https://www.nature.com/articles/s41586-024-07254-x

• Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S*, Binder M*. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. Nature Communications, 2024; Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. * share senior authorship. JIF 17. https://www.nature.com/articles/s41467-024-45378-w

• Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S*, Funke JJ*, Dietz H*. Programmable multispecific DNA-origami-based T-cell engagers. Nat Nanotechnology, 2023; Nov;18(11):1319-1326. doi: 10.1038/s41565-023-01471-7. * share senior authorship. JIF40. https://www.nature.com/articles/s41565-023-01471-7

• Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti Ch, Carlini E, Nandi S, Strzalkowski T, Lorenzini  T, Stock S, Müller P, Dörr J, Seifert M, Cadilha B, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner Ch, Beltrán E, Herold T, Paquet D,  Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S. (2023). Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nature Biotechnology, 41 (11), 1618-1632. doi:10.1038/s41587-023-01684-0. JIF2022=68,2. https://pubmed.ncbi.nlm.nih.gov/36914885/

• Briukhovetska, D., Suarez-Gosalvez, J., Voigt, C., Markota, A., Giannou, A. D., Schubel, M., Jobst, J., Zhang, T., Dorr, J., Markl, F., Majed, L., Muller, P. J., May, P., Gottschlich, A., Tokarew, N., Lucke, J., Oner, A., Schwerdtfeger, M., Andreu-Sanz, D., Grunmeier, R., Seifert, M., Michaelides, S., Hristov, M., Konig, L. M., Cadilha, B. L., Mikhaylov, O., Anders, H. J., Rothenfusser, S., Flavell, R. A., Cerezo-Wallis, D., Tejedo, C., Soengas, M. S., Bald, T., Huber, S., Endres, S., & Kobold, S. (2023). T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity, 56(1), 143-161 e111. doi:10.1016/j.immuni.2022.12.010. JIF2021=43,4. https://pubmed.ncbi.nlm.nih.gov/36630913/
  
• Briukhovetska, D., Dorr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021). Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 21(8), 481-499. doi:10.1038/s41568-021-00363-z. JIF2021=69,8. https://pubmed.ncbi.nlm.nih.gov/34083781/
  
• Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmebarek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, Endres S, Kobold S. (2021). T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 5 (11), 1246-1260. doi:10.1038/s41551-021-00737-6. JIF2021=29,23. https://www.nature.com/articles/s41551-021-00737-6
• Cadilha B, Benmebarek MR, Dorman K, Oener A, Lorenzini T, Obeck H, Väntinnen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Maerkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. (2021). Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumor. Science Advances, 7 (24). doi:10.1126/sciadv.abi5781. JIF2022=13,6. https://pubmed.ncbi.nlm.nih.gov/34108220/
  
• Benmebarek MR, Cadilha B, Hermman M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger Ch, Brauchle B, Rohrbacher L, Oener A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein Ch, Subklewe M, Endres S, Hopfner KP, Kobold S. (2021). A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 35, 2243-2257. JIF2021=12,88. https://pubmed.ncbi.nlm.nih.gov/33414484/
  
• Di Pilato M*, Kfuri-Rubens R*, Pruessmann J*, Ozga AJ*, Messemaker, M, Cadilha B, Sivakumar R, Cianciaruso Ch, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR. (2021). CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell, 184 (17), 4512-4530. *contributed equally. doi:10.1016/j.cell.2021.07.015.  JIF2022=66,85. https://www.sciencedirect.com/science/article/abs/pii/S0092867421008564?dgcid=co author

• Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez J, Kobold S, Gires O, Wang H. (2019). Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Science Advances, 5 (6), eaav4275.doi:10.1126/sciadv.aav4275. JIF2022=13,6. https://pubmed.ncbi.nlm.nih.gov/31223646/

• Ferrari de Andrade, L., Tay, R. E., Pan, D., Luoma, A. M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K. F., Jr., Harvey, C. J., Kobold, S., Pyrdol, J. W., Yoon, C., Yuan, G. C., Hodi, F. S., Dranoff, G., & Wucherpfennig, K. W. (2018). Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science, 359(6383), 1537-1542. doi:10.1126/science.aao0505. JIF2021=47,73. https://pubmed.ncbi.nlm.nih.gov/29599246/
  

• Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, Endres S, Kobold S. (2017). Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences. 114 (49), 12994-12999. *contributed equally. doi:10.1073/pnas.1705165114. JIF2021=12,77. https://pubmed.ncbi.nlm.nih.gov/29150554/

• Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#. (2015). Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. The Journal of the National Cancer Institute, 107. *contributed equally to this study, # share senior authorship. JIF2021=11,81. http://www.ncbi.nlm.nih.gov/pubmed/26105028

• Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, Endres S. (2014). Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. The Journal of the National Cancer Institute. 107:364. JIF2021=11,81. https://pubmed.ncbi.nlm.nih.gov/25424197/

• Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufmann A, Düwell P, Lindner M, Koch I, Heidegger S, Merk M, Rothenfußer S, Schnurr M, Huber RM, Sauter G, Wilczak W, Endres S. (2013). Interleukin-22 is frequently expressed in small-and large- cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. Journal of Thoracic Oncology, 8:1032-1042. JIF2021=20,12. https://pubmed.ncbi.nlm.nih.gov/23774470/